In Brief This Week: Myriad Genetics, Crescendo Bioscience; Illumina, BaseHealth; Atossa Genetics; Sygnis; IDna Genetics; Interleukin Genetics | GenomeWeb

NEW YORK (GenomeWeb News)– Myriad Genetics disclosed last week that Crescendo Bioscience recorded $27.3 million in revenues and a net loss of $41.1 million in 2013. Myriad acquired the autoimmune diagnostics company for $245 million in March. Crescendo spent $12.1 million on R&D last year and $26.4 million on SG&A. It ended the year with $3.1 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.